k4dd1

Stock Investor 🤙

[Jake Wujastyk @Jake__Wujastyk]

$NVDA Red or green tomorrow?

[Surf Air @SurfAir]

FAA Names OperatorOS as an Authorized System for Electronic Signatures and Recordkeeping $SRFM

Louis Saint-Cyr, President of Airline Operations of Surf Air Mobility, said: “OperatorOS has helped us transform our business, making our airline operations more efficient, reliable, and profitable. Many Part 135 operators still run on paper records and manual processes, and we see the FAA’s authorization of OperatorOS as a system of record as a vote of confidence in our software that will help unlock the commercial opportunity for OperatorOS as we bring it to other operators."

Read more: https://t.co/Mxp6Gp2gzr

[Humacyte @humacyte]

🚨 Symvess® acellular tissue engineered vessel-tyod reaches a new commercial milestone in Arizona.

Humacyte is pleased to announce that Jeromy Brink, MD, a board-certified vascular and endovascular surgeon in Phoenix, performed the first post-BLA approval Symvess implants in Arizona.

This milestone reflects continued market adoption of Symvess as hospitals and surgeons add an important on-demand treatment option for appropriate vascular injury patients.

After gaining access to the first-in-class product, Dr. Brink has already performed four Symvess implants in Phoenix, AZ and described Symvess as the “most revolutionary advancement in open surgical bypass in 30 years.”

Symvess is the first and only FDA-approved bioengineered human vessel and is available off the shelf in the operating room for adults with extremity arterial injury when autologous vein graft is not feasible.

For more details, read the full press release here: 🔗https://t.co/p1oyPHKCMj

Learn more about Humacyte at https://t.co/iZqsLFtDWD

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://t.co/Eg2XmrWRso

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life-threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

#Humacyte #Symvess #RegenerativeMedicine #VascularSurgery #BioengineeredTissue #MedTech #TraumaCare $HUMA

Trademarks are the property of Humacyte Global, Inc.
© 2026 Humacyte Global, Inc. All rights reserved.

[k4dd1 @k4dd1xx]

@JamieFInvests Yea not bad

[k4dd1 @k4dd1xx]

@Mariusz_Invest Ur not alone 🤦

[k4dd1 @k4dd1xx]

Anyone buying this?? @srfm

[Blossom @meetblossomapp]

Alex Karp said Palantir can sustain +100% growth for the next 18 months...

That would nearly 3X Palantir by 2028.

$PLTR

[k4dd1 @k4dd1xx]

Shorter getting back in on sivers
Arrowstreet Capital has reportedly become a new publicly disclosed short seller
Citadel Securities has also appeared as a new public short seller
@SiversSemicond

[k4dd1 @k4dd1xx]

Finally getting closer @humacyte
18.8.26

[k4dd1 @k4dd1xx]

Finally getting closer @humacyte
18.8.26

[Surf Air @SurfAir]

Surf Air Mobility $SRFM Q2 2026 Highlights:

Revenue of $29.5M, within guidance.

Adjusted EBITDA loss of $10.5M, within guidance.

Signed first SurfOS enterprise software contract with Wheels Up, worth up to $12M over the term.

Expanded partnership with Palantir Technologies, adding engineering and go-to-market commercial resources.

Surf On Demand private charter delivered its highest revenue and highest flight volume quarter since inception.

Reduced existing convertible note principal by 64% and lowered monthly cash amortization payments by up to 50%.

BETA Technologies began electric aircraft cargo demonstration flights across Hawaii.

Reaffirmed full year 2026 guidance and issued Q3 2026 guidance.

Read more: https://t.co/jmubHJDlW8

[Shay Boloor @StockSavvyShay]

Anthropic signs a $9B compute deal with $RIOT 😳

[Surf Air @SurfAir]

Surf Air Mobility Reports Second Quarter 2026 Financial Results, Meeting Revenue and Adjusted EBITDA Guidance $SRFM

Read more: https://t.co/MIFh3jqNJG

[k4dd1 @k4dd1xx]

@stevehill1mil What can I say ?? 🤔

[k4dd1 @k4dd1xx]

@j1nv3st Don't worry !

[Sivers-Semiconductors @SiversSemicond]

We're pleased to announce that Sivers has received a new $8.2M production order from @allspaceltd for Ka-band Beamforming ICs.

The order underscores Sivers' growing momentum in defense and commercial satcom, where our BFICs are helping enable next-generation multi-orbit satellite communications platforms.

For full details visit: https://t.co/QDfIQf4orV

#Satcom #SpaceTech #Semiconductors #DefenseTech

[amit @amitisinvesting]

GUYS

REMEMBER THAT RANDOM COMPANY PALANTIR GOT 1.8M SHARES IN YESTERDAY FOR PAYMENT OF OUTSTANDING RECEIVABLES

Surf Air Mobility $SRFM

They just published a video today showing how they are using $PLTR Palantir...

Makes sense now that Palantir took an equity stake

[Stocktology @Stocktology_]

@CantoRobinHood Another high risk company I like that’s been getting quietly accumulated is $SRFM. I like the trades that retail doesn’t play. I want them to come after I’m positioned.

[k4dd1 @k4dd1xx]

Avg decrease $srfm